First Wave Biopharma, headquartered in Boca Raton, Florida, develops nonsystemic therapies for gastrointestinal diseases and went public in October 2016. Its key programs include latiglutenase, capeserod, and adrulipase.
ENTO has been in the news recently: Mereo BioPharma Group plc (MREO) is experiencing increased investor interest due to a 90% success probability for its drug setrusumab, currently trading at $4.50. Meanwhile, Kaida Biopharma is preparing to initiate a Phase 1 study for its ovarian cancer treatment KAD101 in 2025, targeting a significant unmet patient need of 90%.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
